Index Dynamics and Upcoming Entries

The Nasdaq‑100 closed the day of record at 31,224.7 on 2026‑10‑05, comfortably below its 52‑week high of 31,361.4 but well above the 52‑week low of 22,841.4. The index has advanced more than 23 % year‑to‑date, a performance that has been unevenly distributed across constituent stocks. While half of the components trade in the red or have risen less than 10 %, a handful of names have surged by several hundred percent, contributing substantially to the overall gain.

ETF Movements Focused on the Index

Several European ETF issuers have released net asset value (NAV) announcements for products that track or invest in the Nasdaq‑100.

  • Amundi Nasdaq‑100 Target Income UCITS ETF (NSDT) – Amundi disclosed its NAV as of 07‑Oct‑2026 at 09:06 CET/CEST.
  • Amundi Core Nasdaq‑100 Swap UCITS ETF Acc – A similar update was released at 09:05 CET/CEST on the same day.

These disclosures indicate active management and ongoing investor interest in income‑focused and synthetic strategies tied to the index’s performance.

Company‑Specific News Driving Volatility

Moderna Inc. (MRNA)

Moderna’s shares closed 6.95 % higher at $203.21 on Monday, closing 2.72 % below its 52‑week high of $208.90. The stock’s 7 % jump ahead of its scheduled addition to the Nasdaq‑100 reflects heightened demand from both institutional investors and retail traders. The price advance outpaced the S&P 500’s 0.66 % gain, underscoring the index’s tech‑heavy orientation and the premium placed on pharmaceutical innovation.

Anthropic

Reports from Coinpedia and Reuters suggest that Anthropic, a prominent artificial‑intelligence firm, is preparing a Nasdaq listing this fall. Marketing could begin as early as mid‑October, with a potential listing before the November midterms. While no filing has been submitted, the prospect of a rapid index entry could bring Anthropic into the radar of index‑fund managers within weeks, amplifying its exposure and potentially driving short‑term volatility.

Investor Sentiment and Outlook

  • Wall Street and Retail Attention – Articles from The Fool highlight the top two Nasdaq‑100 stocks to buy and discuss Vanguard ETFs that have outperformed the index while facing near‑term tests. These pieces reflect a broader trend of investors seeking high‑growth exposure while remaining cautious about valuation levels.
  • Retail Concerns over Valuation – Yahoo Finance noted that while MRNA’s rally is buoyed by its upcoming index inclusion, retail investors are echoing concerns about whether the company’s valuation justifies its price, a sentiment that may influence short‑term trading dynamics.

Market Context

The Nasdaq‑100’s record highs in early October underscore the sustained rally of technology and growth sectors. However, the uneven distribution of gains suggests that momentum is concentrated in a few key names, and any adverse news or regulatory developments affecting those companies could precipitate sharper corrections.

In sum, the Nasdaq‑100 continues to demonstrate robust performance, supported by strong individual company moves and active ETF participation. Upcoming listings and index additions, notably from companies like Anthropic and Moderna, are likely to add liquidity and volatility, offering both opportunities and risks to investors navigating the technology‑heavy landscape.